Core B: Single Cell Protein and RNA Sequencing Core

核心 B:单细胞蛋白质和 RNA 测序核心

基本信息

  • 批准号:
    10334092
  • 负责人:
  • 金额:
    $ 5.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-08-01 至 2022-06-02
  • 项目状态:
    已结题

项目摘要

Core B Summary Core B serves all 4 projects in this PPG for all RNA sequencing needs, including bulk and single cell RNA- sequencing (scRNA-Seq), protein sequencing by oligonucleotide-tagged antibodies (Ab-Seq), T- and B-cell receptor sequencing (TCR-Seq and BCR-Seq) and ATAC-Seq. Core B is responsible for all quality controls along the workflow. Core B staff consists of wet lab staff and bioinformaticians. They interact with postdocs, technicians, epidemiologists and PIs from the Human Clinical Cardiovascular and Biostatistics Core (Clinical Core C) and from each of the four projects. Workflows are established for mouse (macrophages, sorted T cells) and human (PBMC) cells. Hashtags and antibodies are fully validated, including thresholding, which improves data quality by eliminating signal from unbound antibody and non-specific antibody binding. The previous version of this core (core E in the 2016 Hedrick PPG) was the first group world-wide to use scRNA- Seq in atherosclerosis research. We established and published guidelines for workflows and quality controls in scRNA-Seq, batch effect, doublet and dead cell removal. Core B provides wet lab and bioinformatics service plus well-developed interfaces with all 4 projects and core C. For Ab-Seq, we validated a 192 oligonucleotide- tagged human antibody panel (Biolegend), run on 10x Genomics 5’, which will be used for Ab-Seq in most of the proposed human studies. For mice, we use the Biolegend 138 mouse antibody panel with 10x Genomics 5’. Using this platform, we have successfully assembled tens of thousands of TCRα and β chain pairs (scTCR- Seq) and BCR heavy and light chain pairs (scBCR-Seq). All 4 projects use core B. The specific aims are: (1) To provide the highest quality scRNA-Seq, scAb-Seq, scATAC-Seq, scTCR-Seq and scBCR-Seq for mouse and human samples, including fully documented and rigorous quality controls, designing and optimizing antibody panels and advice on all bioinformatics issues. (2) To provide the highest quality bulk RNA-Seq and ATAC-Seq for mouse and human samples, including fully documented and rigorous quality controls and support for experimental design and planning. (3) To effectively and seamlessly interface with postdocs, technicians, epidemiologists and PIs from the Clinical Core C and from each of the four projects, including sample shipping, receiving, thawing, data processing, visualization and delivery. To provide these services, we have built a team of wet lab technicians, bioinformaticians and computational biologists. Interfaces with all projects and core C are established and working well.
核心B摘要 Core B为所有RNA测序需求(包括大量和单细胞RNA-)提供了该PPG中的所有4个项目 测序(SCRNA-SEQ),通过寡核苷酸标签抗体(AB-SEQ),T和B细胞进行蛋白质测序 受体测序(TCR-SEQ和BCR-SEQ)和ATAC-SEQ。核心B负责所有质量控制 沿工作流程。 B核心员工由湿实验室的工作人员和生物信息学家组成。他们与博士后互动, 来自人类临床心血管和生物统计学核心(临床)的技术人员,流行病学家和PI(临床) 核心C)以及四个项目中的每个项目。为鼠标建立工作流程(巨噬细胞,排序T 细胞)和人(PBMC)细胞。主题标签和抗体已得到充分验证,包括阈值,其中 通过消除未结合抗体和非特异性抗体结合的信号来提高数据质量。这 该核心的先前版本(2016年Hedrick PPG中的核心E)是全球第一个使用SCRNA- 动脉粥样硬化研究中的SEQ。我们建立并发布了工作流和质量控制指南 scrna-seq,批处理效应,Doublet和Dead Ell Encoval。 Core B提供湿实验室和生物信息学服务 再加上所有4个项目和核心C的发达界面。对于AB-Seq,我们验证了192个寡核苷酸 - 标记的人类抗体面板(Biolegend),在10倍基因组学5'上运行,将用于大多数AB-SEQ 拟议的人类研究。对于小鼠,我们将Biolegend 138小鼠抗体面板与10倍基因组学 5'。使用此平台,我们成功地组装了数万个TCRα和β链对(SCTCR- SEQ)和BCR重链和轻链对(SCBCR-SEQ)。所有4个项目均使用核心B。具体目的是:(1) 为鼠标提供最高质量的scrna-seq,scab-seq,scab-seq,scatac-seq,sctcr-seq和scbcr-seq 和人类样本,包括完全记录和严格的质量控制,设计和优化 抗体面板和有关所有生物信息学问题的建议。 (2)提供最高质量的散装RNA-Seq和 用于鼠标和人类样品的ATAC-SEQ,包括完全记录和严格的质量控制和 支持实验设计和计划。 (3)有效并无缝地与博士后接口, 来自临床核心C的技术人员,流行病学家和PI以及四个项目中的每个项目,包括 样品运输,接收,解冻,数据处理,可视化和交付。为了提供这些服务,我们 已经建立了一个由湿实验室技术人员,生物信息学家和计算生物学家组成的团队。与所有人的接口 项目和核心C建立并运行良好。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Klaus F. Ley其他文献

Binding of function‐blocking mAbs to mouse and human P‐selectin glycoprotein ligand‐1 peptides with and without tyrosine sulfation
功能阻断单克隆抗体与小鼠和人 P-选择素糖蛋白配体 1 肽(有或没有酪氨酸硫酸化)的结合
  • DOI:
  • 发表时间:
    2002
    2002
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Aravinda Thatte;S. Ficarro;K. Snapp;M. Wild;D. Vestweber;D. Hunt;Klaus F. Ley
    Aravinda Thatte;S. Ficarro;K. Snapp;M. Wild;D. Vestweber;D. Hunt;Klaus F. Ley
  • 通讯作者:
    Klaus F. Ley
    Klaus F. Ley
Serum levels of soluble intercellular adhesion molecule-1 (sICAM-1) correlate with severity of ileitis in experimental Crohn's disease: A novel marker of small intestinal inflammation
  • DOI:
    10.1016/s0016-5085(00)85325-1
    10.1016/s0016-5085(00)85325-1
  • 发表时间:
    2000-04-01
    2000-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Jesus Rivera-Nieves;R. Cartland Burns;Christopher A. Moskaluk;Theresa T. Pizarro;Klaus F. Ley;Fabio Cominelli
    Jesus Rivera-Nieves;R. Cartland Burns;Christopher A. Moskaluk;Theresa T. Pizarro;Klaus F. Ley;Fabio Cominelli
  • 通讯作者:
    Fabio Cominelli
    Fabio Cominelli
α<sub>4</sub>β<sub>1</sub>integrin (VLA-4) blockade reduces neointimal growth after carotid air desiccation injury in the ApoE (−/−) mouse
  • DOI:
    10.1016/s0735-1097(02)80085-7
    10.1016/s0735-1097(02)80085-7
  • 发表时间:
    2002-03-06
    2002-03-06
  • 期刊:
  • 影响因子:
  • 作者:
    Kurt G. Barringhaus;J.William Phillips;John M. Sanders;Ann C. Czamik;Klaus F. Ley;Ian J. Sarembock
    Kurt G. Barringhaus;J.William Phillips;John M. Sanders;Ann C. Czamik;Klaus F. Ley;Ian J. Sarembock
  • 通讯作者:
    Ian J. Sarembock
    Ian J. Sarembock
共 3 条
  • 1
前往

Klaus F. Ley的其他基金

Mechanism of kindlin-3-dependent integrin activation
kindlin-3依赖性整合素激活机制
  • 批准号:
    10676897
    10676897
  • 财政年份:
    2020
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Mechanism of kindlin-3-dependent integrin activation
kindlin-3依赖性整合素激活机制
  • 批准号:
    10229369
    10229369
  • 财政年份:
    2020
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10112954
    10112954
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10369710
    10369710
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    9895858
    9895858
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10623034
    10623034
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Vascular macrophages and T cells in atherosclerosis
动脉粥样硬化中的血管巨噬细胞和 T 细胞
  • 批准号:
    10565907
    10565907
  • 财政年份:
    2019
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Core E: Cell sorting, CyTOF and RNA-Seq
核心 E:细胞分选、CyTOF 和 RNA-Seq
  • 批准号:
    10188604
    10188604
  • 财政年份:
    2017
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Super-resolution confocal microscope
超分辨率共焦显微镜
  • 批准号:
    9274885
    9274885
  • 财政年份:
    2017
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
ApoB-specific CD4 T cells in mouse and human atherosclerosis
小鼠和人类动脉粥样硬化中的 ApoB 特异性 CD4 T 细胞
  • 批准号:
    10188608
    10188608
  • 财政年份:
    2017
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:

相似国自然基金

抗体偶联支化糖基聚合物靶向降解SIRPα用于动脉粥样硬化的治疗研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
抗体偶联支化糖基聚合物靶向降解SIRPα用于动脉粥样硬化的治疗研究
  • 批准号:
    82202310
  • 批准年份:
    2022
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
抗氧化低密度脂蛋白人源单链抗体的筛选及其抗动脉粥样硬化研究
  • 批准号:
    81900395
  • 批准年份:
    2019
  • 资助金额:
    21.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
  • 批准号:
    23K15842
    23K15842
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
    Grant-in-Aid for Early-Career Scientists
Deciphering the molecular mechanism of ineffective erythropoiesis in MDS-5q
破译MDS-5q无效红细胞生成的分子机制
  • 批准号:
    10773217
    10773217
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
  • 批准号:
    10652788
    10652788
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Cell-free hemoglobin-oxidized LDL-LOX-1 axis and microvascular hyperpermeability during sepsis
脓毒症期间无细胞血红蛋白氧化的 LDL-LOX-1 轴和微血管通透性过高
  • 批准号:
    10739620
    10739620
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别:
Novel Mechanisms Underlying the Development of Atherosclerosis
动脉粥样硬化发展的新机制
  • 批准号:
    10589484
    10589484
  • 财政年份:
    2023
  • 资助金额:
    $ 5.35万
    $ 5.35万
  • 项目类别: